Global Trial in APG2575 for Patients With CLL/SLL

Part of paid clinical trials in Houston, Texas.

Sponsor
Ascentage Pharma Group Inc.
Study ID
NCT06104566
Phase
PHASE3
Status
Recruiting
Apply to this trial

Conditions

  • CLL/SLL

Eligibility Criteria

Sex
ALL
Age
18 Years - 99 Years
Healthy Volunteers
Not accepted

Interventions

  • lisaftoclax +BTK inhibitor — DRUG
    lisaftolax + BTK inhibitor
  • BTK inhibitor — DRUG
    BTK inhibitor

Study Details

This is a global multicenter, open label, randomized, registrational phase III study to investigate the efficacy and safety of lisaftoclax in combination with BTK inhibitors in CLL/SLL patients who previously treated with BTK inhibitors

Key Dates

Start date
Dec 20, 2023
Status verified
Sep 2025
Primary completion
Oct 20, 2025
Completion
Oct 31, 2027

Study Design

Enrollment
400 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Arm 1
    Combination therapy
  • Active Comparator: Arm 2
    mono therapy

Primary Outcome Measure

PFS [ Time Frame: 12 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
MD Anderson Cancer CenterHoustonTexas77030
Nitin Jain, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
MD Anderson Cancer Center· Houston, TX

Related Studies